Santhera Pharmaceuticals Holding AG Announces Preliminary Unaudited Revenue Results for the Second Half and Full Year of 2016; Provides Earnings Guidance for the Year 2016 and Revenue Guidance for the Year 2017
Net sales for the second half of 2016 of CHF 11.8 million represent an increase of 64% compared to the first half of 2016 (CHF 7.2 million).
For the year 2016, the company expects a net loss of CHF 33 million to CHF 38 million.
For the year 2017, the company expects net sales of Raxone for the currently approved indication to reach CHF 21 million to CHF 23 million.